

FIGURE 1




FIGURE 2

Category	Lexical Element	Lexical Element	Lexical Element
Risk factor (RF) patient history			
Risk due to past history			
RF patient ADR history	Sepsis	Hypersensitivity	Hypersensitivity
RF patient family history			
RF patient concurrent condition			
Risk due to current disease			
RF past drug		Enbrel	<Enbrel component>
RF past drug class			
RF concomitant drug			
RF concomitant drug class			
RF drug-in-question (DIQ) class	DMARD	DMARD	DMARD
RF DIQ	Enbrel (etanercept)	Enbrel (etanercept)	Enbrel (etanercept)
RF difference of gender			
RF age			
Outcome	Sepsis	Hypersensitivity	Hypersensitivity
Outcome origin			
Notes on outcome and resolution			
Prescribing action for DIQ	Contraindication	Contraindication	Contraindication
Follow-up actions			
Follow-up actions cont'd			
Conditional follow-up actions			
FUA condition			
FUA conditional action			
Instructions to patient			
Conditional instructions to patient			
ITP condition			
ITP conditional action			
What to remain alert for			
Not to be used as alternate therapy for			
Parameters to monitor			
What to test or check			
When to test or check			
Why/what to consider			
Prescribing notes to Physician			

FIGURE 3

Category	Lexical Element	Lexical Element
Risk factor (RF) patient history		
Risk due to past history		
RF patient ADR history		
RF patient family history		
RF patient concurrent condition		
Risk due to current disease		
RF past drug		
RF past drug class		
RF concomitant drug		
RF concomitant drug class		
RF drug-in-question (DIQ) class	DMARD	DMARD
RF DIQ	Enbrel	Enbrel
RF difference of gender		
RF age		
Outcome	New infection	sepsis
Outcome origin		
Notes on outcome and resolution		
Prescribing action for DIQ	Continue	Discontinue
Follow-up actions	Monitor closely	
Follow-up actions cont'd		
Conditional follow-up actions	Discontinue if new infection becomes serious	
FUA condition		
FUA conditional action		
Instructions to patient		
Conditional instructions to patient		
ITP condition		
ITP conditional action		
What to remain alert for		
Not to be used as alternate therapy for		
Parameters to monitor		
What to test or check		
When to test or check		
Why/what to consider		
Prescribing notes to Physician		

FIGURE 4

Figure 5: Sample of mapping a conditional text statement to a rule structure, using dictionary terms

Label Text:

Celebrex should not be given to patients who have demonstrated allergic-type reactions to sulfonamides.


Risk Category			
Risk Factor Patient past history			
Risk Factor Patient ADR history		Allergic-type reactions	
Risk factor Patient family history			
Risk Factor Patient concurrent condition			
Risk factor Past drug			
Risk factor Past Drug Class		Sulfonamides	
Risk Factor Concomitant Drug			
Risk Factor Concomitant drug class			
Risk Factor Drug-in-Question Class			
Risk factor Drug-in-Question	Celebrex		
Outcome			
Outcome Origin			
Additional Notes on Outcome and Resolution			
Prescribing Action for Drug-in-Question	Contraindicated		
Follow-up Actions			
Follow-up Actions cont'd			
Conditional Follow-up Actions			
FUA Condition			
FUA Conditional action			
Instructions to Patient			
Conditional Instructions to Patient			
IIP Condition			
IIP Conditional action			
What to Remain Alert For			
Not to be used as Alternate Therapy For			
Parameters to Monitor			
What to Test/Check			
When to Test/Check			
Why/What to Consider			
Additional Prescribing Note to Physician			
Note General			

[illegible]

622


[illegible]622

Journal of Health Politics, Policy and Law




[illegible]


a) Celebrex should not be given to patients with the aspirin triad.



8b) The symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAID's.



c) Emergency help should be sought in cases where anaphylactoid reactions occur.






FIGURE 9

Drug information source 210 is a stack of three overlapping rectangular boxes, each containing illegible text. To the left of the top box are three small black dots arranged in a descending diagonal line.




Figure 10